ITK and B-cell chronic lymphocytic leukemia: JAK/STAT signaling is also activated downstream of BCR signaling in CLL cells (28), and ibrutinib, a BTK/ITK inhibitor, has been shown to downregulate STAT3 phosphorylation in CLL patient B cells (29).